Targeted Oncology

, Volume 4, Issue 2, pp 135–142

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

Authors

  • Kamalesh Sankhala
    • Institute for Drug DevelopmentCancer Therapy and Research Center at the University of Texas Health Science Center
  • Alain Mita
    • Institute for Drug DevelopmentCancer Therapy and Research Center at the University of Texas Health Science Center
  • Kevin Kelly
    • Institute for Drug DevelopmentCancer Therapy and Research Center at the University of Texas Health Science Center
  • Devalingam Mahalingam
    • Institute for Drug DevelopmentCancer Therapy and Research Center at the University of Texas Health Science Center
  • Francis Giles
    • Institute for Drug DevelopmentCancer Therapy and Research Center at the University of Texas Health Science Center
    • Institute for Drug DevelopmentCancer Therapy and Research Center at the University of Texas Health Science Center
Review

DOI: 10.1007/s11523-009-0107-z

Cite this article as:
Sankhala, K., Mita, A., Kelly, K. et al. Targ Oncol (2009) 4: 135. doi:10.1007/s11523-009-0107-z

Abstract

Mammalian target of rapamycin (mTOR) has emerged as an important target for cancer therapy. Rapamycin has a distinct, well-documented toxicity profile and most of the toxicity data has been reported in patients with organ transplantation. Newer mTOR inhibitors have slightly different pharmacokinetic properties, yet they present toxicity profiles similar to rapamycin. Most of these toxicities are mild to moderate in severity and can be managed clinically by dose modification and supportive measures. Mucositis and pneumonitis are the most commonly reported toxicities, but they rarely lead to treatment discontinuation. Pathogenesis of pneumonitis is uncertain, but various hypotheses have been suggested, including cell-mediated immune response to the drug.

Keywords

mTOR inhibitorsToxicityPulmonary toxicityHyperlipidemiaMucositisNewer mTOR inhibitorsRapamycin

Copyright information

© Springer-Verlag 2009